Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKUS Akouos	$13.29	$13.29	$2.32 ▼ $13.60	$490.88M	-0.55	344,411 shs	440 shs
AVDL Avadel Pharmaceuticals	$17.81 -0.1%	$15.81	$9.50 ▼ $18.85	$1.61B	1.6	1.21 million shs	452,410 shs
FSTX F-star Therapeutics	$7.12	$6.19	$2.07 ▼ $7.12	$156.50M	0.85	709,213 shs	N/A
IOBT IO Biotech	$1.42 -2.1%	$1.62	$0.82 ▼ $2.64	$93.55M	0.5	129,798 shs	73,378 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKUS Akouos	0.00%	0.00%	0.00%	0.00%	0.00%
AVDL Avadel Pharmaceuticals	+0.91%	+2.53%	+9.73%	+28.85%	+77.49%
FSTX F-star Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
IOBT IO Biotech	-0.68%	-1.36%	-13.95%	-18.99%	-22.46%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKUS Akouos	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	2.9307 of 5 stars	4.5	1.0	0.0	0.0	3.0	1.7	0.6
FSTX F-star Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	3.3951 of 5 stars	3.5	5.0	0.0	0.0	2.5	1.7	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKUS Akouos	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	3.00	Buy	$22.57	26.73% Upside
FSTX F-star Therapeutics	N/A	N/A	N/A	N/A
IOBT IO Biotech	3.00	Buy	$8.33	486.85% Upside

Current Analyst Ratings

Latest FSTX, AKUS, AVDL, and IOBT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/6/2024	IOBT IO Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
3/5/2024	AVDL Avadel Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
3/5/2024	AVDL Avadel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$18.00 ➝ $23.00
3/5/2024	AVDL Avadel Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$27.00 ➝ $29.00
3/5/2024	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $25.00
3/5/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
2/6/2024	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKUS Akouos	N/A	N/A	N/A	N/A	$4.90 per share	N/A
AVDL Avadel Pharmaceuticals	$27.96M	57.70	N/A	N/A	$0.98 per share	18.17
FSTX F-star Therapeutics	$21.17M	7.39	N/A	N/A	$4.70 per share	1.51
IOBT IO Biotech	N/A	N/A	N/A	N/A	$2.02 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKUS Akouos	-$86.67M	-$2.62	N/A	N/A	N/A	N/A	-45.09%	-36.86%	N/A
AVDL Avadel Pharmaceuticals	-$160.28M	-$2.04	N/A	20.95	N/A	N/A	-198.06%	-84.51%	5/2/2024 (Estimated)
FSTX F-star Therapeutics	-$31.28M	-$1.82	N/A	N/A	N/A	N/A	-57.08%	-42.40%	N/A
IOBT IO Biotech	-$86.08M	-$2.16	N/A	N/A	N/A	N/A	-66.28%	-59.61%	5/9/2024 (Estimated)

Latest FSTX, AKUS, AVDL, and IOBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/5/2024	Q4 2023	IOBT IO Biotech	-$0.36	-$0.40	-$0.04	-$0.40	N/A	N/A
3/4/2024	Q4 2023	AVDL Avadel Pharmaceuticals	-$0.28	-$0.32	-$0.04	-$0.29	$17.41 million	$19.45 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKUS Akouos	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FSTX F-star Therapeutics	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKUS Akouos	N/A	17.30	17.30
AVDL Avadel Pharmaceuticals	N/A	3.64	3.36
FSTX F-star Therapeutics	0.15	3.38	3.38
IOBT IO Biotech	N/A	9.37	9.37

Ownership

Institutional Ownership

Company	Institutional Ownership
AKUS Akouos	N/A
AVDL Avadel Pharmaceuticals	69.19%
FSTX F-star Therapeutics	31.50%
IOBT IO Biotech	54.76%

Insider Ownership

Company	Insider Ownership
AKUS Akouos	4.80%
AVDL Avadel Pharmaceuticals	4.00%
FSTX F-star Therapeutics	3.20%
IOBT IO Biotech	3.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AKUS Akouos	103	36.94 million	35.16 million	Not Optionable
AVDL Avadel Pharmaceuticals	154	90.58 million	86.95 million	Optionable
FSTX F-star Therapeutics	84	21.98 million	21.28 million	Not Optionable
IOBT IO Biotech	68	65.88 million	63.58 million	Not Optionable

FSTX, AKUS, AVDL, and IOBT Headlines

Source	Headline
	IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting globenewswire.com - April 24 at 4:30 PM
	IO Biotech (IOBT) Price Target Decreased by 11.11% to 8.16 msn.com - April 17 at 10:15 AM
	IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decline in Short Interest americanbankingnews.com - April 16 at 4:22 AM
	IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness globenewswire.com - April 15 at 8:30 AM
	IO Biotech presents cancer vaccine data at AACR investing.com - April 11 at 12:59 AM
	IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 globenewswire.com - April 9 at 12:00 PM
	IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer globenewswire.com - April 5 at 8:30 AM
	IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 50.3% in March marketbeat.com - March 29 at 9:42 PM
	IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials finance.yahoo.com - March 7 at 3:57 PM
	Buy Recommendation for IO Biotech on Strong Data Prospects and Undervalued Stock Position markets.businessinsider.com - March 6 at 11:14 PM
	IO Biotech Inc IOBT morningstar.com - March 6 at 6:14 PM
	IO Biotech GAAP EPS of -$0.40 misses by $0.02 msn.com - March 6 at 6:14 PM
	IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting globenewswire.com - March 6 at 4:11 PM
	IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023 investorplace.com - March 5 at 11:33 PM
	IO Biotech Announces 2023 Fourth-Quarter and Year-End Results globenewswire.com - March 5 at 4:40 PM
	Fierce Biotech Fundraising Tracker '24: Frontier closes $80M series C; Firefly Bio fueled by $94M fiercebiotech.com - February 28 at 6:51 PM
	IO Biotech to Present at 44th Annual Cowen Health Care Conference globenewswire.com - February 26 at 4:05 PM
	What's Next for Iovance Biotherapeutics Stock? msn.com - February 4 at 7:42 AM
	IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24% finance.yahoo.com - January 15 at 7:53 AM
	IO Biotech: A Phase 3 Company Getting No Respect seekingalpha.com - January 3 at 9:34 AM
	IO Biotech Inc’s latest rating changes from various analysts knoxdaily.com - January 1 at 8:54 AM
	IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial finance.yahoo.com - December 21 at 8:45 AM
	We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate finance.yahoo.com - December 19 at 7:40 AM
	IO Biotech executive discloses purchase of 10K shares msn.com - November 27 at 7:14 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akouos

NASDAQ:AKUS

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Avadel Pharmaceuticals

NASDAQ:AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

F-star Therapeutics

NASDAQ:FSTX

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

IO Biotech

NASDAQ:IOBT

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial